Novavax financials
$10.82+0.19%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $56.7M | $139.5M | $147.1M | $70.4M | $239.2M | $666.7M | $88.3M | $84.5M | $415.5M | $93.9M | $291.3M | $187.0M |
| Gross profit | $42.5M | $108.8M | $125.0M | $48.9M | $223.9M | $652.5M | $51.6M | $23.9M | $369.2M | $34.6M | $136.4M | $88.1M |
| Gross margin | 74.9% | 78.0% | 85.0% | 69.5% | 93.6% | 97.9% | 58.5% | 28.3% | 88.9% | 36.9% | 46.8% | 47.1% |
| Operating income | -$54.9M | -$15.4M | $14.2M | -$178.0M | $101.1M | $515.5M | -$131.1M | -$134.0M | $161.0M | -$144.8M | -$183.6M | -$125.6M |
| Net income | -$53.4M | -$9.5M | $17.5M | -$202.4M | $106.5M | $518.6M | -$81.0M | -$121.3M | $162.4M | -$147.6M | -$178.4M | -$130.8M |
| Net margin | −94.2% | −6.8% | 11.9% | −287.3% | 44.5% | 77.8% | −91.8% | −143.5% | 39.1% | −157.2% | −61.2% | −69.9% |
| Diluted EPS | $-0.32 | $-0.06 | $0.10 | $-1.25 | $0.62 | $2.93 | $-0.57 | $-0.76 | $0.99 | $-1.05 | $-1.63 | $-1.26 |
| EBITDA | -$51.9M | -$12.4M | $20.2M | -$74.4M | $108.6M | $523.9M | -$118.6M | -$121.3M | $172.1M | -$132.7M | -$183.6M | -$114.3M |
| Operating cash flow | -$72.8M | -$32.4M | -$39.5M | $107.8M | -$127.5M | -$185.5M | -$173.2M | -$144.8M | $314.3M | -$83.6M | -$176.8M | -$39.7M |
| Free cash flow | -$73.4M | -$33.7M | -$41.7M | $105.8M | -$128.0M | -$187.1M | -$175.4M | -$146.8M | $311.1M | -$90.8M | -$185.9M | -$58.0M |
| Diluted shares | 164.6M | 163.3M | 175.2M | 162.4M | 177.2M | 177.6M | 142.9M | 160.0M | 165.9M | 139.9M | 109.4M | 103.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $191.5M | $228.4M | $240.6M | $268.0M | $253.7M | $263.3M |
| Short-term investments | $527.9M | $562.0M | $494.4M | $494.9M | $358.6M | $468.1M |
| Total debt | $297.3M | $295.1M | $248.8M | $251.1M | $228.5M | $228.7M |
| Total assets | $955.6M | $1.04B | $1.18B | $1.18B | $1.34B | $1.29B |
| Total liabilities | $1.15B | $1.19B | $1.30B | $1.34B | $1.30B | $1.37B |
| Shareholders' equity | -$190.7M | -$144.8M | -$127.8M | -$156.7M | $37.6M | -$75.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology